Previous 10 | Next 10 |
home / stock / mycof / mycof news
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, will be participating in the Wonderland: Miami. Hosted by Microdose, the upcoming event is scheduled fo...
DENVER, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company focused on the treatment of mental health disorders and addiction, ...
The Mydecine Innovations Group portfolio includes a robust portfolio of NCEs (New Chemical Entities) and medicines based on compounds found in psychedelics, including four lead clinical trial drug candidates, as well as digital health solutions Through an exclusive partnership with Appl...
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) , a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has successfully synthesized a novel psilocin analogue, a tryptamine. This achievement means improved p...
Further strengthens the Company’s drug development pipeline of tryptamines by introducing novel psilocin analogues containing enhancements in safety and efficacy tailored for medical use DENVER, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO...
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations PR Newswire NEW YORK , Oct. 18, ...
Palm Beach, FL –October 14, 2021 – FinancialNewsMedia.com News Commentary – Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the medical cost of mental health conditions is estimated to ri...
Mydecine to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th PR Newswire DENVER , Oct. 6, 2021 /PRNewswire/ -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), a biopharmaceutical c...
DENVER, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health disorders and addiction, today announced that it...
DENVER, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA ) (“Mydecine” or the “Company”) , a biopharmaceutical company focused on the treatment of mental health and addiction, today announced...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) Vancouver, British Columbia, July 5, 2024— TheNewswire – Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) is pleased to confirm that further to its news release dated June 13, 2024, ...
(TheNewswire) Vancouver, British Columbia, May 31, 2024 - TheNewswire - Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order granted on May 2...
(TheNewswire) Vancouver, British Columbia – TheNewswire - May 16, 2024— Mydecine Innovations Group Inc. (the “ Company ”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) (AQSE: MYIG) provides this update on the status of a management cease trade order gr...